AMYLYX Phase 1/2 Clinical Trial
Recently published preclinical data demonstrate initial proof-of-concept for the therapeutic development of AMX0035 (sodium phenylbutyrate and taurursodiol) in Wolfram syndrome
Entries by Paul Schlereth
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
Recently published preclinical data demonstrate initial proof-of-concept for the therapeutic development of AMX0035 (sodium phenylbutyrate and taurursodiol) in Wolfram syndrome
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 Helios Clinical Trial
Phase 2 HELIOS Interim Data in Wolfram Syndrome
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation
KU Leuven Spin-off Enables More Targeted Gene Therapy
KU Leuven Spin-off Enables More Targeted Gene Therapy
TreatWolfram Newsletter Update — September 2024
We are getting to the end of the TREATWOLFRAM trial, and the last participants will be having their last visits this October. We then hope to collect all outstanding data from study sites by the end of the year.
Clinical Trial Update by Dr. Barrett — January 2024
Our research teams have kept busy and I would like to use this letter to keep you updated on our progress. The TREATWOLFRAM trial is now in its final year. It has been a long journey to get here, navigating medicine manufacture problems, BREXIT, Covid, and supply issues.